A 28-year-old woman with severe rheumatic mitral stenosis (MVA 0.8 cm²) presents with acute-onset rapid atrial fibrillation (ventricular rate 140 bpm) and pulmonary edema. She is hemodynamically stable. What is the drug of choice for immediate rate control in this patient?

Explanation

## Acute Rate Control in Mitral Stenosis with Atrial Fibrillation **Key Point:** In a hemodynamically **stable** patient with severe mitral stenosis (MS) and rapid atrial fibrillation (AF), **IV beta-blockers (metoprolol or esmolol)** are the preferred first-line agents for acute rate control. They rapidly slow AV nodal conduction, increase diastolic filling time across the stenotic valve, and have only mild negative inotropy — making them safe in this setting. ### Why IV Beta-Blockers Are Preferred | Feature | IV Beta-blocker | IV Verapamil | IV Diltiazem | IV Digoxin | |---------|-----------------|--------------|--------------|------------| | **Onset** | 2–5 min | 3–5 min | 2–3 min | 30 min–2 hrs | | **Negative inotropy** | Mild | Marked | Moderate | Minimal | | **Safety in stable MS + AF** | **Excellent** | Use with caution | Second-line | Safe but slow | | **Preferred for acute rate control** | **Yes** | No | If beta-blockers fail/contraindicated | No (too slow) | ### Mechanism of Action 1. **Beta-1 blockade** → ↓ AV nodal conduction velocity → slows ventricular rate 2. **↑ Diastolic filling time** → allows more time for blood to cross the stenotic mitral valve → ↓ left atrial pressure → ↓ pulmonary edema 3. **Mild negative inotropy** → acceptable in a hemodynamically stable patient; improved diastolic filling compensates 4. **Rapid IV onset** (2–5 min) → prompt symptom relief **Clinical Pearl:** Esmolol is particularly useful in the acute setting due to its ultra-short half-life (~9 min) — adverse effects resolve quickly if they occur. Metoprolol is preferred when sustained rate control is needed. ### Why Not the Other Options? - **Digoxin (A):** Has a very slow onset (30 min–2 hrs for rate control), making it inadequate for **acute** rate control. It is appropriate for **chronic** AF rate control in MS or as an adjunct. The verifier's reasoning that beta-blockers worsen hemodynamics in MS is incorrect — this concern applies to hypertrophic obstructive cardiomyopathy (HOCM), not MS. In MS, slowing the heart rate is beneficial. - **Verapamil (B):** Strong negative inotropic effect; use with caution in MS with pulmonary edema. Not preferred over beta-blockers. - **Diltiazem (D):** A reasonable **second-line** option if beta-blockers are contraindicated or fail, but not the drug of choice. The explanation's prior language of "absolute contraindication" was overstated — diltiazem can be used cautiously as an alternative. ### Treatment Algorithm: Acute AF + MS ``` Acute AF + MS + Rapid Ventricular Rate ↓ Hemodynamically stable? YES → IV Beta-blocker (metoprolol / esmolol) ← DRUG OF CHOICE NO → Emergency DC Cardioversion ↓ Rate controlled (<110 bpm)? YES → Transition to oral therapy + anticoagulation NO → Consider IV diltiazem or add digoxin as adjunct ``` **High-Yield:** The key pathophysiology in MS is that tachycardia shortens diastole, reducing time for left ventricular filling across the stenotic valve, raising left atrial pressure and worsening pulmonary edema. Rate control with IV beta-blockers directly addresses this by prolonging diastole. [cite: Harrison's Principles of Internal Medicine, 21e, Ch. 297; Braunwald's Heart Disease, 12e]